Business Context and Reporting Period
This Form 8-K Current Report was filed by IOVANCE BIOTHERAPEUTICS, INC. on December 14, 2020. The filing discloses the appointment of a new Chief Financial Officer and Treasurer, effective December 14, 2020. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in San Carlos, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the leadership transition in the finance department:
- Appointment: Jean-Marc Bellemin was appointed as Chief Financial Officer and Treasurer.
- Departure: Michael C. Swartzburg, previously the Vice President of Finance and Principal Financial Officer, will step down from that role but will remain as the Company's Principal Accounting Officer.
Management Commentary, Compensation, and Risks
The filing details the Executive Employment Agreement for Mr. Bellemin, effective December 14, 2020:
- Base Salary: $450,000 annually.
- Equity Grant: An option to purchase 150,000 shares of common stock with a ten-year term. The exercise price is the closing trading price on the Effective Date.
- Vesting Schedule:
- One-third (50,000 shares) vests on the one-year anniversary.
- The remaining two-thirds vest quarterly over the subsequent two years.
- Bonus Plan: Eligible for an annual cash bonus with a maximum potential of 40% of base salary, contingent on individual and corporate objectives.
- Severance: In the event of termination without cause, Mr. Bellemin is entitled to six months of base salary. Additional severance provisions apply in the event of a "change of control."
- Employment Status: Employment is "at-will" with no specific term.
Background: Mr. Bellemin previously served as Executive Vice President of Finance and CFO of Gritstone Oncology, Inc. (2018–2020) and held senior financial roles at Actelion Pharmaceuticals US Inc. and Guerbet Group.
Investor Verification Checklist
- Verify the closing stock price on December 14, 2020, to determine the exercise price of the 150,000 stock options granted.
- Review the subsequent filing referenced in the text for the full text of the Executive Employment Agreement.
- Monitor future filings for the specific corporate and individual performance objectives tied to the annual bonus plan.
- Confirm the transition timeline for Michael C. Swartzburg's continued role as Principal Accounting Officer.